Trending...
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
Download
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
- FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
- Colorado: Governor Polis Signs Law to Rename Cesar Chavez Day to Farm Worker Day
- HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
- J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
- Colorado: Supreme Court Restricts States' Ability to Protect LGBTQ Youth From Inhumane Conversion Therapy
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
- Bibamba Artisan Chocolate Named "Best Chocolatier" by Westword in Best of Denver 2026
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
- IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
- AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
- Ananda Scientific (https://www.linkedin.com/company/ananda-scientific)
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
Filed Under: Business
0 Comments
Latest on Colorado Desk
- Canyons & Chefs Launches New Page Dedicated to Private Chef Bachelor and Bachelorette Experiences Across Colorado
- Canyons and Chefs Launches New Page for Cannabis-Infused Private Chef Dining Across Colorado
- DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
- CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
- Denver Apartment Finders Updates Its RiNo Page to Help Renters Navigate Denver's River North Market
- Explosive $10 Billion Counter-Drone Market with AI-Powered Defense Ecosystem: ZenaTech, Inc. (N A S D A Q: ZENA)
- High-Value Execution Phase Begins: Bitcoin Bancorp Ignites Texas Rollout of Digital Asset ATM Network: Bitcoin Bancorp (Stock Symbol: BCBC) $BCBC
- Canyons and Chefs Launches New Page for Elopements and Intimate Weddings Catering in Colorado
- Backed By Google And Nvidia, Imagiportal Supercharges Ai Personas With 10,000+ Elevenlabs Voices
- UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
- SelfCare is now HealthCare across America
- Colorado Springs Airport Monthly Update - February 2026
- Colorado: It's Kickoff Time! Governor Polis Wishes The Denver Summit FC Good Luck In First Home Game
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- GDE Tree Services Expands Operations into Sydney, NSW
- Tuckwell Machinery Expands CNC Range to Support Australian Cabinet Makers
- The Inner Power of Emotional Self-Leadership
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- Colorado: Governor Polis Signs Bills Into Law